In this article, we will look at the 7 Best Longevity Stocks to Buy Now.
Longevity stocks are getting more attention as investors look for companies tied to longer lifespans, healthier aging, and rising demand for care. The theme is broader than drugmakers. It includes chronic disease treatment, preventive healthcare, diagnostics, medical technology, fitness, nutrition, telehealth, and active aging.
Pictet Asset Management says “We are living longer,” but adds that the challenge is making sure “those extra years are spent in good health.” The firm expects “preventative health” to become a bigger focus for governments, healthcare companies, and individuals, which supports the case for diagnostics, screening, obesity care, and medtech. UBS describes longevity as an opportunity that helps people “live longer, healthier lives,” and estimates that annual revenues in the global longevity market could reach “USD 8tr” by 2030, with healthcare alone representing a “USD 2.2tr opportunity.” J.P. Morgan Private Bank adds that “Health & Wellness is now experiencing a renaissance,” supported by GLP-1 drugs, an aging global population, telehealth, mental health, and “wearable and fitness technology.” Against this backdrop, longevity stocks deserve a closer look.
With that in mind, let’s take a look at the 7 Best Longevity Stocks to Buy Now.
Our Methodology
We used the Finviz screener to identify longevity stocks that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
7. Johnson & Johnson (NYSE:JNJ)
On June 8, 2026, Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc. for $1B in cash. Firefly Bio is advancing its proprietary Firelink degrader antibody conjugate platform, which is focused on KRAS-driven tumors. Johnson & Johnson said the Firelink DAC platform bolsters its oncology pipeline and is designed to deliver a selective protein degrader to tumor cells while avoiding healthy cells. The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.
On June 3, 2026, Johnson & Johnson announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study of nipocalimab in adults with moderate-to-severe Sjogren’s disease. The company said patients with elevated autoantibody and immunoglobulin G levels showed greater clinical response rates, with the findings supporting continued study of nipocalimab in the ongoing Phase 3 DAFFODIL study. Also on June 3, Johnson & Johnson said nipocalimab met the primary endpoint in the Phase 2 JASMINE study in adults with moderate-to-severe systemic lupus erythematosus, reducing disease activity at 24 weeks and showing sustained reduction through 52 weeks.
Johnson & Johnson also said the JASMINE study showed greater response versus placebo plus background medication in participants who tested positive for lupus-associated autoantibodies. At Week 52, 53.6% of patients receiving nipocalimab 15 mg/kg achieved an SRI-4 response, compared with 39.7% for placebo plus background medication. The company said nipocalimab had a safety profile consistent with previous studies, and no new safety signals were identified.
Johnson & Johnson researches, develops, manufactures, and sells healthcare products worldwide.
6. Amgen Inc. (NASDAQ:AMGN)
On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In an analysis of 6,002 patients, Repatha, when added to statins or other LDL-C-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% compared with placebo. Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization by 21%.
On June 5, 2026, Goldman Sachs lowered the firm’s price target on Amgen Inc. to $389 from $425 and maintained a Buy rating on the shares. Goldman Sachs adjusted its model after Amgen disclosed in its Q1 earnings that the IRS audit for 2016 to 2018 had escalated into a formal dispute, with the company receiving a notice of proposed adjustment.
Earlier in June, Amgen announced that the European Commission granted marketing authorization for Imdylltra as a monotherapy for adults with extensive-stage small cell lung cancer who require systemic therapy after disease progression on or after first-line platinum-based chemotherapy.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
5. UnitedHealth Group Incorporated (NYSE:UNH)
On June 8, 2026, JPMorgan raised the firm’s price target on UnitedHealth Group Incorporated (NYSE:UNH) to $466 from $420 and maintained an Overweight rating on the shares. JPMorgan updated its healthcare service models.
On the same day, Mizuho raised the firm’s price target on UnitedHealth Group Incorporated to $460 from $440 and maintained an Outperform rating on the shares. Mizuho said the managed care sector is entering a “more stable and predictable” policy environment, with policy-related surprises likely to moderate from the elevated levels of the past three years. The firm said this should let investors focus on company fundamentals, pricing recovery, and embedded earnings power.
On June 4, 2026, BofA analyst Kevin Fischbeck upgraded UnitedHealth Group Incorporated to Buy from Neutral with a price target of $450, up from $420. Fischbeck said incoming data points make it harder to view the strong Q1 as purely tied to weak flu and storms, and said UnitedHealth should lead a broader managed care rally if utilization trends continue to moderate.
UnitedHealth Group Incorporated operates as a health care company in the United States and internationally.
4. Novo Nordisk A/S (NYSE:NVO)
On June 7, 2026, Novo Nordisk A/S (NYSE:NVO) presented Phase 3 results from its Reimagine 1-3 trials, which showed significant reductions in HbA1c and weight in adults with type 2 diabetes. The Reimagine trials met their primary endpoints, showing significant HbA1c reductions, and met their confirmatory secondary endpoints for bodyweight reduction. The data were presented during a late-breaking symposium at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, alongside publication of the Reimagine 1 and 2 results in The Lancet Diabetes & Endocrinology and the Reimagine 3 results in The Lancet.
Also on June 7, Novo Nordisk A/S announced new real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide 1 mg. The analysis compared escalation to semaglutide 2 mg with switching to tirzepatide. By one year, both groups were associated with similar proportions of patients achieving HbA1c of less than 7%, while patients on semaglutide 2 mg had a statistically significantly higher event rate for achieving weight loss greater than or equal to 5%.
Novo Nordisk A/S also presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS trials at the ADA Scientific Sessions, highlighting data on semaglutide across weight-related conditions. Senior medical director Andrea Traina said the analyses add to the clinical evidence for semaglutide across obesity, cardiovascular disease, and metabolic dysfunction-associated steatohepatitis.
Novo Nordisk A/S researches, develops, manufactures, and distributes pharmaceutical products.
3. Gilead Sciences, Inc. (NASDAQ:GILD)
On June 5, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) applauded the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. CEO Daniel O’Day said South Africa is “at the heart of global efforts to end HIV,” and that Gilead is working with country leadership, the Global Fund, and the U.S. State Department through PEPFAR to bring lenacapavir to communities most in need ahead of a broader rollout of generic versions.
On June 2, 2026, Gilead Sciences, Inc. announced Phase 3 results in primary biliary cholangitis showing that Livdelzi led to significantly more patients achieving normalization of alkaline phosphatase, or ALP, compared with placebo after 52 weeks. The primary endpoint was defined as ALP less than or equal to 1.0 upper limit of normal and a greater than or equal to 15% decrease from baseline. Cynthia Levy of the University of Miami Miller School of Medicine said the IDEAL results further support the efficacy and safety profile of Livdelzi.
On May 27, 2026, Gilead Sciences, Inc. shared post hoc analysis data from the ongoing Phase 3 ASSURE study showing high and sustained ALP normalization rates in people with primary biliary cholangitis. Among 50 participants, 83% of evaluable participants achieved composite ALP normalization at 12 months, while 74% achieved the same endpoint at 24 months. Gilead said Livdelzi was generally well tolerated, with no treatment discontinuations due to adverse events and no new safety signals observed with up to two years of follow-up.
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in areas of unmet medical need in the United States, Europe, and internationally.
2. Abbott Laboratories (NYSE:ABT)
On June 7, 2026, Abbott Laboratories (NYSE:ABT) announced new data showing that diabetic ketoacidosis, or DKA, “remains an important” but often undetected health concern for people with both Type 1 and Type 2 diabetes. The findings, shared at the American Diabetes Association’s 86th Scientific Sessions, showed sharp increases in DKA-related hospitalizations across all age groups nationwide. Mahmood Kazemi, chief medical officer for Abbott’s diabetes care business, said the data show that preventing DKA starts with recognizing risk earlier.
On May 27, 2026, Abbott Laboratories announced that it secured the CE Mark for its dual glucose-ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, giving users real-time visibility into glucose levels and rising ketones that can lead to a DKA emergency. Abbott said it plans to begin launching Libre Duo systems in select European countries later this year.
Also on May 27, Abbott said the American Cancer Society released updated colorectal cancer screening guidelines that reaffirm Cologuard and Cologuard Plus as preferred noninvasive screening options for adults aged 45 and older at average risk for CRC.
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide.
1. Pfizer Inc. (NYSE:PFE)
On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is now indicated in the U.S. for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients 6 years and older with hemophilia A with or without factor VIII inhibitors, or hemophilia B with or without factor IX inhibitors.
On June 7, 2026, Pfizer Inc. presented detailed Phase 2b results for berobenatide, an investigational monthly GLP-1 receptor agonist peptide, at the 86th Scientific Sessions of the American Diabetes Association. The company said the VESPER-1, 2, and 3 studies provided proof of concept for berobenatide as a potential first-in-class monthly GLP-1 RA peptide, showed favorable tolerability, and highlighted potential advantages from monthly delivery and a 0.5 mL injection volume.
On May 31, 2026, Pfizer Inc. announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 Breakwater trial. Pfizer said median progression-free survival was nearly doubled with the BRAFTOVI combination regimen versus the comparator.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
READ NEXT: 15 High Growth Stocks to Buy and Hold for the Next Decade and 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years
